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Abstract
Background: Four subtypes of hepatocellular adenomas (HCA) are recognized: hepatocyte-nuclear-factor-1α
mutated (H-HCA), β-catenin-mutated type with upregulation of glutamine synthetase (b-HCA), inflammatory type
(IHCA) with serum-amyloid-A overexpression, and unclassified type. Subtyping may be useful since b-HCA appear to
have higher risk of malignant transformation. We sought to apply subtype analysis and assess histological atypia,
correlating these with next-generation sequencing analysis.
Methods: Twenty-six HCA were stained with serum amyloid A (SAA), liver fatty acid-binding protein (LFABP),
glutamine synthetase (GS), and β-catenin IHC, followed by analysis with a targeted multiplex sequencing panel.
Results: By IHC, 4 HCA (15.4 %) were classified as b-HCA, 11 (42.3 %) as IHCA, 9 (34.6 %) as H-HCA, and two (7.7 %)
unclassifiable. Eight HCA (30.8 %) showed atypia (3 b-HCA, 4 IHCA and 1 H-HCA). Targeted sequencing confirmed
HNF1A mutations in all H-HCA, confirming reliability of LFABP IHC in identifying these lesions. CTNNB1 mutations
were detected in 1 of 4 (25 %) of GS/β-catenin-positive cases, suggesting that positive GS stain does not always
correlate with CTNNB1 mutations.
Conclusions: Immunohistochemistry does not consistently identify b-HCA. Mutational analysis improves the
diagnostic accuracy of β-catenin-mutated HCA and is an important tool to assess risk of malignancy in HCA.
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Background
Hepatocellular adenomas (HCA) are rare benign liver
tumors with the capacity to undergo malignant trans-
formation. Epidemiologic studies report the prevalence
of HCA is approximately 3–4 cases per 100,000 people
in Europe and North America, [1] and lower in Asian
countries [2]. The highest prevalence is described in fe-
males taking oral contraceptives, but other risk factors,
such as anabolic steroid use, obesity and metabolic syn-
drome are described [2–5]. Inherited syndromes such as
glycogenosis type 1, maturity-onset diabetes of the
young type 3 (MODY3), and familial adenomatous
polyposis have also been linked to the development of
HCA [3, 5, 6]. HCA can be solitary or multiple, with
“liver adenomatosis” defined as presence of multiple
HCA (>10) of any size involving all liver segments [7].
The majority of HCA are benign and some regress with-
out surgical intervention. However, serious complica-
tions can occur. Notably, hemorrhage is described in up
to one fourth of patients, mainly associated with large
(>5 cm) lesions. Furthermore, 9 % of HCA may trans-
form into hepatocellular carcinoma (HCC) with risk fac-
tors including male sex, androgen use, large tumors
(>5 cm) and β-catenin-mutated HCA [5]. In these com-
plicated cases, early surgical removal may improve
* Correspondence: marcelafa@hotmail.com
Elizabeth Margolskee and Fei Bao are co-first authors.
†Equal contributors
1Department of Pathology and Cell Biology, Columbia University Medical
Center, 630 W 168th Street, VC14-238, New York, NY 10032, USA
Full list of author information is available at the end of the article
© 2016 Margolskee et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Margolskee et al. Diagnostic Pathology  (2016) 11:27 
DOI 10.1186/s13000-016-0475-5
patient outcomes [8, 9]. Therefore, there is interest in
developing diagnostics to preemptively identify high-risk
cases and guide clinical management. Imaging studies
may identify a proportion of HCA with relatively high
sensitivities and specificities, but some cannot be accur-
ately differentiated from HCC [10, 11]. In these cases,
histological evaluation becomes essential for diagnosis.
In the last decade, four subtypes of HCA have been
identified based on genotype-phenotype analyses [12].
Inactivating mutations in the HNF1A (TCF1) gene caus-
ing loss of hepatocyte nuclear factor 1α (HNF-1α) ex-
pression define H-HCA, which are characterized
histologically by marked steatosis and bland hepatocyte
cytology [12, 13]. A second subtype, with activating
mutations of β-catenin (b-HCA), is associated with an
increased risk of malignant transformation into HCC
[9, 12, 14–16]. A third subtype (IHCA) is marked by in-
flammatory infiltrates or telangiectatic features by hist-
ology with increased serum amyloid A (SAA) and C
reactive protein (CRP) expression by IHC. IHCA has been
linked with activating mutations in several genes including
IL6ST, FRK, STAT3, JAK1, and GNAS [17, 18]. Whole ex-
ome sequencing has also demonstrated that there is over-
lap between b-HCA and IHCA in some adenomas that
harbor mutations in both the β-catenin and IL6ST genes
[18]. Furthermore, in addition to previously reported mu-
tations in exon 3, a smaller proportion of b-HCA carry
mutations in exons 7 and 8 of CTNNB1; however no in-
creased risk of malignant transformation was noted in
these patients [18]. Finally, a small proportion of HCA
does not appear to fall into any of the above categories
and were considered unclassifiable by current testing ap-
proaches (UHCA).
Based on this classification, subtyping of HCA by immu-
nohistochemistry has been used with some success [19].
Briefly, loss of liver fatty-acid binding protein (LFABP)
staining results from HNF-1A mutation in H-HCA, and in-
creased SAA immunoreactivity serves as a marker for
IHCA. Upregulation of a downstream CTNNB1 target
gene, glutamine synthase (GS), is seen in b-HCA, as well as
nuclear β-catenin staining. It has been postulated that the
immunophenotypic subtypes closely parallel specific histo-
logic features and molecular alterations, but limitations
have been observed by numerous studies and detailed stud-
ies correlating morphology, immunohistochemical profile
and mutation analysis are lacking [3, 12, 20, 21]. The aim
of our study was to apply the HCA classification system
based on histologic features and immunohistochemical
profiles and correlate the findings with molecular analysis.
Methods
Case selection and histopathological evaluation
HCA cases diagnosed between January 1994 and December
2012 were retrieved from our pathology department
archives. For resection specimens, representative sections
of tumor and non-tumorous liver were reviewed for histo-
logical features. The presence of multiple adenomas (2 or
more tumors) had been previously assessed by gross organ
review and representative sections of each adenoma were
examined by microscopy. For biopsies, only tumor tissue
was available for review and radiology reports were
reviewed to determine the presence of multiple aden-
omas. Retrospective chart reviews were performed to
collect additional demographic data including age, gen-
der, related medical history and clinical follow-up. The
study was approved by the Institutional Review Board
at Columbia University Medical Center.
Hematoxylin and eosin (H&E) stained slides, reticulin
and Masson’s trichrome stains as well as immunohisto-
chemical studies (IHC) were used to evaluate general
morphologic and immunophenotypic features. All cases
were reviewed by 3 pathologists (MAS, EM and FB).
Tumor characteristics evaluated on routine H&E stained
slides included: steatosis (mild = 0–33 %; moderate = 33–
66 %; marked= > 66 % of the lesion), inflammation, si-
nusoidal dilatation (telangiectasia), ductular prolifera-
tion, nuclear atypia (nuclear pleomorphism, increased
nuclear:cytoplasmic ratio) and architectural atypia
(gland-like or acinar growth). Atypia was defined as the
presence of any of the following: (1) nuclear atypia, (2)
any degree of architectural atypia, and/or (3) focal loss
of reticulin staining.
Immunohistochemistry
Immunohistochemistry for LFABP (ABCAM, Cambridge,
UK, 1:100 dilution), SAA (ABCAM, Cambridge, UK,
1:100 dilution), β-catenin (BD Bioscience, San Jose, CA,
1:50 dilution) and GS (Millipore, Billerica, MA, 1:2000)
was performed in all cases using standard laboratory tech-
niques in the Ventana Benchmark Ultra platform (Tucson,
AZ, USA). GS IHC was scored as 0 (negative, or weak
perivascular staining in <10 % of the tumor), 1+ (perivas-
cular staining or pseudo-maplike pattern of >10 % of the
tumor), and 2+ (diffuse strong staining), as previously de-
scribed [19]. Pseudo-maplike GS pattern has been previ-
ously described as interconnected clusters of hepatocytes
beyond perivascular lesions, connected by inconspicuous
bands of positive hepatocytes [22]. β-catenin IHC was
graded as 0 (membranous staining) or 1 (nuclear staining
in any percentage of tumor cells). LFABP and SAA stains
were scored from 0 to 2+ (Score of 0 = negative or <10 %
staining, 1 + = 10–50 % staining, and 2+ = >50 % positive
staining). In most cases, we used adjacent non-tumoral
liver as internal negative controls, including negative SAA
staining, membranous β-catenin pattern, and normal cen-
trilobular GS positivity. CD34 immunohistochemical
stains (DAKO, Carpinteria, CA, 1:200) were performed on
atypical cases to evaluate for the presence of sinusoidal
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capillarization, as previously described [23]. In select
cases, glypican-3 (Cell Marque, Rocklin, CA, 1:100) im-
munohistochemistry was also performed.
Molecular analysis
Multiplex targeted DNA next generation sequencing was
performed in 18 of 26 cases. DNA was extracted from fro-
zen and/or formalin-fixed paraffin-embedded tumor tissue
using QIAamp DNA Mini Kit (QIAGEN, Germany) ac-
cording to manufacturer’s specifications. DNA was
quantitated by fluorometry with the Invitrogen Qubit
fluorometer and Quant-iT dsDNA BR Assay Kit (Life
Sciences, Carlsbad, CA), as recommended by the
manufacturer. The samples were sequenced using the
TruSeq Amplicon Cancer Panel (MiSeq system, Illu-
mina, CA), which covers 225 amplicons within 48
cancer-related genes, including 2 amplicons correspond-
ing to exons 3 and 4 of HNF1A gene, and one amplicon
representing exon 3 of CTNNB1 gene.
Whole exome sequencing on an expanded panel of
467 tumor-specific genes, including HNF1A, CTNNB1
(all exons), IL6ST, STAT3, GNAS, and JAK1, was per-
formed in a subset of cases. This test requires higher
amount of DNA and could only be performed in 11
cases with sufficient DNA (cases 2–4, 6–10, 13, 14 and
26). Target capture and enrichment were performed with
the SureSelect Hybrid Capture system (Agilent Technolo-
gies, Santa Clara, CA) using custom probes. cDNA Librar-
ies were then quantified using qPCR, diluted to 2nM and
pooled for analysis on Illumina HiSeq 2500 using Illumina
TruSeq v3 chemistry (Illumina, San Diego, CA).
Data deconvolution was performed using CASAVA
Software (Illumina, CA). Files meeting QC metrics were
used for mapping and variant calling using NextGENe
Software (Softgenetics, State College, PA). Reads were
aligned to the hg19 reference genome. Variant calls with
allele prevalence >1 % in the 1000 Genome Project, <3
variant reads, ambiguous alignments, quality score <10,
and allele frequency <10 % were excluded. Variants were
cross referenced with COSMIC, PROVEAN, and SIFT
prediction tools [24].
Statistical analysis
For categorical variables, Fisher’s exact test was used.
One-way Kruskal-Wallis test was used for nonparametric
data, including immunohistochemical scoring. Continuous
variables were compared using a two-tailed student t-test




A total of 26 HCA cases (22 resections and 4 biopsies)
were included in this study (male = 5, female = 21, mean
age 36.2 ± 16 years). Ten patients had multiple aden-
omas (38.5 %) with an average number of 6 lesions per
patient (range: 2–14). The average size of HCA was
8.2 ± 4.5 cm (range: 1-18 cm). Detailed clinical history
and follow-up data was available in 22 cases. One or
more risk factors for the development of HCA at the
time of resection (e.g. use of oral contraceptives, ana-
bolic steroid use, obesity, prior pregnancy) was identi-
fied in the majority of cases (16/23, 70 %). Among the
female patients, use of oral contraceptives (OCP) was
identified in 12 of 21 (57.1 %) cases. One of 5 male pa-
tients (20 %) reported anabolic steroid use. We did not
identify any case of glycogen storage disease, vascular
diseases or mature-onset diabetes of the young type 3
(MODY3). None of the 22 patients with follow-up data
developed hepatocellular carcinoma (mean overall sur-
vival of 4.2 years). One patient died of colon cancer.
The patient’s demographics and follow-up data are
summarized in Table 1.
Histopathological and immunohistochemical analysis
First, we attempted to classify each adenoma based on
IHC pattern, as previously described [19]. Briefly,
LFABP-negative cases were classified as H-HCA (Fig. 1).
HCA with strong and diffuse GS staining (score 2+)
and/or β-catenin nuclear staining, regardless of the SAA
staining status, were categorized as b-HCA (Fig. 2). The
remaining HCA with SAA positivity (scores 1+ to 2+)
were classified as IHCA (Fig. 3).
By applying the above criteria, we identified 4 b-HCA
(15.4 %), 11 IHCA (42.3 %), and 9 H-HCA (34.6 %).
Two cases (7.7 %) were negative or weakly positive for
GS, negative for SAA, and positive for LFABP, and were
therefore unclassifiable (Table 2).
By immunohistochemistry, we found significant over-
lap between the b-HCA and IHCA subtypes. Focal SAA
staining (1+, <50 % of cells) was present in 2 out of 4 b-
HCA (cases 1 and 2). Conversely, 5 IHCA with 1+ or 2+
SAA staining showed weak, heterogeneous GS expres-
sion (score 1+) (cases 5–7, 10 and 13). We chose not to
classify these as mixed β-catenin/inflammatory HCA
based solely on immunohistochemistry because none of
them demonstrated strong positivity for both GS and
SAA. Cases with loss of LFABP did not show any stain-
ing for GS, except for one H-HCA case with strong (2+)
GS staining (Table 2, case 16). In addition, strong (2+)
SAA staining was present in 5 of 9 H-HCA (LFABP-
negative) cases and might have resulted from proximity
to areas of tumor necrosis or hemorrhage within the
tumor, findings identified in at least 3 cases. Nuclear β-
catenin staining was present in 3 of 5 (60 %) GS positive
(2+) cases, but was limited to rare to few cells corre-
sponding to less than 5 % of total tumor area and pre-
dominantly located in perivascular areas (Fig. 2c).
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During the interpretation phase of this study, we en-
countered two technical difficulties. First, we found that
LFABP IHC can sometimes be faint in the non-
neoplastic liver resulting in an inconspicuous gradient
between native liver and tumor. In such cases, LFABP
staining was repeated in multiple tumor sections in
order to obtain acceptable results. Second, the few cases
with nuclear β-catenin positivity were difficult to evalu-
ate since nuclear positivity could only be appreciated in
less than 5 % of the tumor cells.
Molecular analysis
Results of targeted DNA sequencing analysis were corre-
lated with the classification obtained by immunohisto-
chemical analysis (Table 2). HNF1A mutations were
identified in all analyzed H-HCA (5/5, 100 %) and in no
other HCA subtype (p value = 0.001). The codon alterations
were Gly207Asp, Asn237Ser, Asn237Lys, Leu281Gln and
Tyr286Cys, 3 of them previously reported in H-HCA [18].
CTNNB1 gene alterations were identified in 2 cases:
one b-HCA harboring both a CTNNB1 gene deletion
(c.114_119del; p.38_40del) and a TP53 gene mutation
(Ile251Phe) (case 1); and a second case originally classi-
fied as IHCA based on IHC results (ie. strong diffuse
SAA positivity and focal GS staining), found to have a
missense CTNNB1 mutation (Ser45Pro). This case also
carried an IL6ST mutation (c.566_577del; p.189_193del)
and was thus reclassified as a mixed β-catenin/inflam-
matory HCA (bIHCA) (case 7, Fig. 4b). CTNNB1 alter-
ations in exons 7 and 8 were not identified in the 11
tumors analyzed by whole-exome sequencing. Six tu-
mors classified as IHCA due to 2+ SAA staining had no
mutations in the IHCA-related pathways.
A total of 4 cases were reclassified following molecular
analysis. One case was the bIHCA described above. The
other 3 tumors, initially classified as b-HCA (2+ GS stain-
ing), were reclassified because molecular analysis demon-
strated no abnormalities in the CTNNB1 gene. Two of
them carried IL6ST gene alterations (IL6ST c. C657A;
Pro216His and IL6ST c.554_568del; p.185_190del) and










1 F 66 Y 6.4 365 N
2 M 22 N 13 365 N
3 M 24 N 18 182.5 N
4 F 7 N 15.1 4962 N
5 F 11 Y 11 3235 N
6 M 34 N 14.9 612 Obesitya
7 F 40 N 8 547.5 OCP
8 F 32 Y 2.5 n/a OCP
9 F 38 N 4.4 n/a OCP
10 F 39 N 7.1 4745 OCP
11 F 19 N 2.5 1460 n/a
12 F 29 N 6.3 1104 OCP
13 F 17 Y 7.6 2988 N
14 F 54 N 10 246 Prior pregnancy
15 F 45 Y 9 939 OCP
16 M 25 N 8.5 730 Androgen use
17 F 39 Y 10 1095 OCP, prior
pregnancy
18 F 34 Y 8 n/a OCP, prior
pregnancy
19 F 42 N 5.5 n/a OCP
20 F 58 Y 4 2190 OCP, obesity,
prior pregnancy
21 F 41 Y 4.5 2190 OCP
22 F 75 N 5.5 deceased n/a
23 M 32 N 18 1713 n/a
24 F 38 Y 1 7190 N
25 F 52 N 7.2 1255 N
26 F 29 N 6.3 1095 OCP
Abbreviations: F female, M male, N absent, Y Present, n/a data not available,
OCP oral contraceptive use, aObesity is defined as BMI > 30
Fig. 1 Histological features of HNF-1a inactivated hepatocellular adenoma (H-HCA). a, H-HCA with steatosis and b, loss of LFABP expression (H&E
and IHC X 20). c, higher magnification showing marked steatosis (H&E x100)
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were reclassified as IHCA. The third case had no alter-
ations in CTNNB1, HNF1A, IL6ST, STA3, GNAS or JAK1
genes and final classification could not be confirmed by
molecular studies (Fig. 4a).
Following classification by molecular testing (Table 2,
last column), we analyzed the histological features of
each subtype (Figs. 1, 2 and 3). All cases classified as H-
HCA by IHC showed steatosis of variable degree. IHCA
(n = 9) showed features of telangiectasia (n = 9, 100 %),
focal inflammation (n = 6, 66.7 %) and ductular reaction
(n = 4, 44.4 %). Mild to moderate steatosis was occasion-
ally seen IHCA (n = 2, 22.2 %). Telangiectasia, a feature
commonly associated with IHCA, was seen in the bI-
HCA (case 7). No cases classified as b-HCA, IHCA or
UHCA showed marked steatosis.
In rare occasions, limited DNA concentration or DNA
degradation may limit detection of mutations and dele-
tions in tumor samples. To circumvent this issue, DNA
was obtained from both frozen and formalin-fixed tumor
samples and sequenced using two different platforms.
This approach was feasible in 12 of our 18 analyzed
samples and yielded reproducible sequencing results.
By our sequencing methods, LFABP IHC captured all
H-HCA cases and was 100 % specific, whereas
combination of GS and β-catenin IHC predicted β-
catenin mutations with a sensitivity of 50 %, specificity
of 75 %, and PPV of 20 %. Correlation between histo-
logical features, IHC results and molecular analysis
showed that LFABP loss and tumor steatosis were sig-
nificantly associated with H-HCA (p = 0.001 and 0.036,
respectively). Not surprisingly, telangiectasia was prefer-
entially present in IHCA (p = 0.0002) (Table 3).
Evaluation of atypia in HCA
Eight cases (30.8 %) displayed one of more atypical fea-
tures (Table 2, example in Fig. 5). By molecular testing,
these cases were classified as b/b-IHCA (2 of 2, 100 %),
IHCA (4 of 9, 44.4 %), H-HCA (1 of 5, 20 %), and
UHCA (1 of 2, 50 %). Nuclear atypia was present in 7
cases (87.5 %). Gland-like or acinar growth was seen in 4
of 8 cases (50 %). Reticulin staining showed focal
(<1 mm) loss of reticulin framework in 6 cases (75 %).
By CD34 immunostaining, focal or patchy sinusoidal
capillarization was seen in 6 cases (75 %), but diffuse
CD34 staining classically described in malignant hepato-
cellular lesions was not identified. Glypican-3 immuno-
histochemistry was negative in all atypical cases.
Atypical HCA were more frequently present in male
Fig. 2 Histological features of beta-catenin activated hepatocellular adenoma (b-HCA). a, Lower power micrograph showing border of b-HCA
(middle and right) with normal liver (left) (H&E x20). b, Diffuse GS expression in b-HCA (right) in contrast to the focal perivenular staining in the
normal liver tissue (left) (IHC X 20). c, diffuse and strong GS staining (right panel) vs. focal β-catenin nuclear staining (left panel) in b-HCA (IHC X 200)
Fig. 3 Histological features of inflammatory hepatocellular adenoma (IHCA). a, IHCA with telangiectasia and focal inflammation (H&E X 20). b, Diffuse
serum amyloid-A expression within the tumor (IHC X 20). c, Higher magnification micrograph highlighting inflammation (lower right) and telangiectasia
(upper left) (H&E X 100)
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patients, but this result did not reach statistical signifi-
cance (3 of 5 males [60 %] vs. 5 of 21 females [23.8 %],
p = 0.28). Similarly, patient age was not significantly dif-
ferent in patients with atypical HCA (mean age 28 vs.
39.9 years, p = 0.07).
Discussion
Hepatocellular adenomas have a small risk of malig-
nant transformation with estimated rates of less than
5 % [3, 25–27]. Recent advances in the morphologic
and molecular classification of HCA identified b-HCA
as the subtype most commonly associated to malignant
transformation. This finding warrants the use of robust
and reliable approaches to identify such tumors [12, 18].
In particular, the status of CTNNB1 mutations in HCA
may offer crucial information regarding management of
some of these patients.
The current HCA classification scheme is based on
the tumor’s morphologic and immunohistochemical char-
acteristics and was originally validated with CTNNB1 and
HNF1A gene sequencing [28]. More recently, high-
throughput sequencing of a large HCA cohort led to the
discovery of novel genetic alterations, [17, 18] including
new hot-spots in CTNNB1 gene in the b-HCA subtype,
and defects in the IL-6/JAK/STAT3 pathway in IHCA.
Our study is one of the first to use a comprehensive
Table 2 Histological, immunohistochemical and mutational analysis of hepatocellular adenomas
Morphological features Immunohistochemistry Mutational Analysis Initial
Classificationb
Final
ClassificationcCase Morphology Atypical features SAA LFABP B-cat GS
1 0 NuA, Lret 1 2 0 2 CTNNB1 c.114_119del; p.38_40del1
TP53 c.T751A; Ile251Phe1,2
b-HCA b-HCA
2 T NuA, AG, Lret 1 2 1 2 IL6ST c.C657A; Pro216His1,2,3 b-HCA IHCA
3 T 0 0 2 1 2 IL6ST c.554_568del; p.185_190del1,3 b-HCA IHCA
4 0 NuA, AG, Lret 0 2 1 2 nm** b-HCA favor b-HCA
5a 0 AG, Lret 1 2 0 1 n/a IHCA n/a
6 T, I NuA, AG, Lret 1 2 0 1 nm** IHCA IHCA
7 T, I, DR NuA 2 2 0 1 CTNNB1 c.T133C; Ser45Pro1,3
IL6ST c.566_577del; p.189_193del1,3
IHCA bIHCA
8 T, I 0 2 2 0 0 nm** IHCA IHCA
9 T, I, DR 0 2 2 0 0 nm** IHCA IHCA
10 T, I, DR 0 2 2 0 1 nm** IHCA IHCA
11 T, DR NuA, Lret 2 2 n/a 0 nm IHCA IHCA
12 T 0 2 2 0 0 n/a IHCA n/a
13a T, I, S (20 %) 0 2 2 0 1 nm** IHCA IHCA
14 T, I, DR, S (60 %) 0 2 2 n/a 0 nm** IHCA IHCA
15a T, I, DR 0 2 2 0 0 n/a IHCA n/a
16 S (30 %) NuA 2 0 0 2 HNF1A c.620G > A; Gly207Asp1,3 H-HCA H-HCA
17 S (20 %) 0 2 0 0 1 HNF1A c.857A > G;Tyr286Cys1 H-HCA H-HCA
18 S (40 %) 0 0 0 0 0 HNF1A c.842 T > A;Leu281Gln1 H-HCA H-HCA
19 S (70 %) 0 0 0 0 0 n/a H-HCA n/a
20 S (80 %) 0 0 0 0 0 HNF1A c.710A > G; Asn237Ser1,3 H-HCA H-HCA
21 S (70 %) 0 2 0 0 0 HNF1A c.710A > T; Asn237Lys1,3 H-HCA H-HCA
22 S (10 %) 0 2 0 n/a 0 n/a H-HCA n/a
23 I, S (30 %) 0 2 0 0 0 n/a H-HCA n/a
24 T, I, S (50 %) 0 0 0 0 0 n/a H-HCA n/a
25a S (10 %) 0 0 2 0 1 n/a UHCA n/a
26 I 0 0 2 0 0 nm** UHCA UHCA
Abbreviations: B-HCA β-catenin activated hepatic adenoma, IHCA inflammatory HCA, bIHCA HCA with mixed IHCA and b-HCA features, H-HCA HNF1A-inactivated
HCA, UHCA unclassifiable HCA, SAA serum amyloid A, LFABP liver fatty acid-binding protein, b-cat β-catenin, GS glutamine synthetase, 0 absent, T telangiectasia, I
inflammation, DR ductular reaction, S Steatosis (% fat), NuA nuclear atypia, AG acinar growth, Lret focal loss of reticulin stain, n/a not available, nm no mutation/
deletion/insertion identified in HNF1A and CTNNB1 exon 3, nm** no mutation/deletion/insertion identified in HNF1A, IL6ST, STAT3, GNAS, JAK1 and CTNNB
(expanded gene analysis)
aOnly biopsy specimen available; bClassification based on IHC alone; cClassification following molecular evaluation (italic font is used to mark cases that were
re-classified after molecular analysis); 1Deleterious alteration by PROVEAN prediction; 2 variant previously described in HCC; 3 variant previously described in HCA
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targeted next-generation sequencing panel to evaluate the
mutational status of HCA and correlate with immunohis-
tochemistry results.
As expected, our study demonstrated HNF1A gene
mutations in all analyzed H-HCA cases, confirming high
accuracy of this marker in the diagnosis of H-HCA.
However, our results suggest limited reliability of GS
and β-catenin immunohistochemistry in predicting β-
catenin mutations. The utility of both markers has been
challenged by other researchers [10, 21, 22, 29, 30].
Lagana et al. showed strong GS positivity in over 50 %
of HCA and Joseph et al. described patchy to diffuse GS
staining in 23 % of IHCA, but no correlation with mo-
lecular studies were available in these studies [22]. In the
present study, seven of 12 GS-positive cases displayed
faint perivascular staining or heterogeneous positivity.
Further molecular evaluation performed in 5 tumors
failed to demonstrate CTNNB1 alterations in 4 cases,
one of which was a biopsy specimen (case 13). These
somewhat controversial staining patterns and their cor-
relation with β-catenin activation have not been fully
characterized and may be a result of localized metabolic
alterations within the tumor [20–22, 31].
In addition, we identified strong GS positivity in four
β-catenin wild-type tumors, including one H-HCA. We
speculate whether these tumors may have activation of
an alternative pathway resulting in GS expression. Berry
et al. described strong GS staining in a peliotic HCA
and suggested that vascular flow alterations and hepatic
parenchymal remodeling may explain increased GS ex-
pression [31, 32].
In our study, GS staining failed to identify 1 of 2 con-
firmed CTNNB1-mutated HCA. Low GS expression in
b-HCA has been previously reported in HCA carrying
the Ser45Pro mutation [33]. Interestingly, the same β-
catenin mutation has been described in HCC and was
not associated with nuclear β-catenin staining, suggest-
ing that some CTNNB1 alterations may not disrupt GS
and β-catenin expression patterns [34]. None of the 11
cases evaluated by whole-exome sequencing carried
large CTNNB1 deletions or mutations in exons 7 or 8,
the latter described in a minority of bHCA and previ-
ously shown to activate β-catenin in HCC cell lines [18].
Caution is warranted in such cases as they show weak
and patchy GS staining and lack nuclear staining of β-
catenin [18].
Fig. 4 Patterns of glutamine synthetase staining in HCA. a, Diffuse GS staining in CTNNB1 wild-type tumor (case 4) (upper right, x 10). b, GS staining of
bIHCA carrying both CTNNB1 and IL6ST alterations (case 7) shows perivascular and focal pseudomap-like pattern (lower aspect, x 10). As
internal positive control, note the normal centrilobular pattern of GS staining of the adjacent non-neoplastic liver
Table 3 Correlation between histological features and molecular classification of HCA
H-HCA (n = 5) b-HCA/bIHCA (n = 2) IHCA (n = 9) UHCA (n = 1) p value
Telangiectasia 0 50 % (1) 100 % (9) 0 0.0002
Inflammation 20 % (1) 50 % (1) 67 % (6) 100 % (1) NS
Ductular Reaction 0 50 % (1) 44 % (4) 0 NS
Steatosis (mean %) 48 % 0 9 % 0 0.04
Atypical features 20 % (1) 100 % (2) 44 % (4) 0 NS
SAA positive (1+/2+) 60 % (3) 100 % (2) 89 % (8) 0 NS
GS positive (1+/2+) 40 % (2) 100 % (2) 56 % (5) 0 NS
LFABP loss 100 % (5) 0 0 0 0.0001
Abbreviations: SAA serum amyloid A, LFABP liver fatty acid-binding protein, GS glutamine synthetase, b-HCA beta-catenin activated hepatic adenoma, bIHCA HCA
with mixed IHCA and b-HCA features, IHCA inflammatory HCA, H-HCA HNF1A inactivated HCA, UHCA unclassifiable HCA, NS not statistically significant (p value >0.05)
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Following molecular analysis, four tumors were reclas-
sified. One case phenotypically classified as IHCA was
reclassified as bIHCA because it carried both a β-
catenin mutation and an IL6ST alteration. Three cases
initially categorized as b-HCA lacked CTNNB1 gene al-
terations. Two of them were re-subtyped as IHCA fol-
lowing identification of IL6ST gene alterations, all of
which previously described in IHCA [17, 35]. The
remaining case carried no mutations in HNF1A or any
of the IHCA-related genes. In this challenging case, the
diagnosis of a β-catenin-activated HCA is favored, but
the lack of molecular evidence for CTNNB1 alterations
suggests alternative mechanisms of β-catenin activation
and GS overexpression in the tumor [36]. This adenoma
was originally resected from a 7-year-old patient with no
known medical conditions, who remains disease-free after
over 13 years of her surgery. HCA occurrence in preadoles-
cence is extremely rare and little is known about the nat-
ural history and pathogenesis of such lesions. Six adenomas
immunophenotypically compatible with IHCA lacked iden-
tifiable mutations in IHCA-associated genes, a finding pre-
viously described by others [18, 27].
A large percentage of HCA showed atypical features
(30.8 %) but no correlation with a specific HCA type was
identified. Other histological features, such as mild steato-
sis and telangiectasia, were not reliable predictors of HCA
subtype as defined by IHC and molecular analysis. In
addition, we identified significant immunohistochemical
overlap between the b-HCA and IHCA subtypes. Some of
these “overlap” lesions, with immunohistochemical fea-
tures of both IHCA and b-HCA, have been previously de-
scribed as carrying CTNNB1 activating mutations [18].
Both β-catenin-mutated cases showed SAA staining and
atypical histological features, but alterations in the inflam-
matory pathway were only present in one case.
There is a strong association between b-HCA and he-
patocellular carcinoma at the time of diagnosis or during
follow-up [19]. In our study, none of our cases pro-
gressed to HCC. One possible explanation is the fact
that our group consisted predominantly of females on
oral contraceptives, features generally associated with
lower risk of malignant transformation [18]. Interest-
ingly, one b-HCA with atypia harbored a CTNNB1 exon
3 deletion (Gly38_Thr40del) and a TP53 mutation
(Ile251Phe), the latter located in a known ‘hotspot’ for
cancer-related alterations and previously described in
HCC [37]. For the purposes of this study, we favor a very
well-differentiated HCC arising from b-HCA. Evason
et al. described HCC-related genetic alterations in β-
catenin-activated adenomas suggesting that some of
these lesions more likely represent low-grade hepatocel-
lular carcinomas [38]. No other HCC-related driver mu-
tations were identified in our study set.
Immunohistochemistry remains the mainstay for HCA
classification due to its relative reliability and rapid turn-
around time, especially when differentiating HCA from
Fig. 5 Histological atypia in HCAs. a, pseudoacinar formation (H&E X 200). b, nuclear atypia (H&E X 200). c, capillarization of the HCA on CD34
immunohistochemical stain (X 100). d, focal loss of reticulin by reticulin silver stain (X 100)
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other lesions, such as focal nodular hyperplasia and he-
patocellular carcinoma [22, 39]. However, given the in-
herent variability in GS staining and the low sensitivity
of β-catenin IHC, we believe that molecular testing
should be used in all HCA cases with equivocal staining
patterns, especially in high-risk patients. Our findings
are limited by the small sample size and must to be con-
firmed by a systematic review of a larger number of
well-characterized HCA including correlation of each
immunohistochemical pattern with mutational profiles
detected by molecular analysis.
Conclusion
In summary, while LFABP immunohistochemistry is reli-
able in identifying H-HCA, GS and β-catenin stains are
weak predictors of β-catenin mutations. Our molecular
analysis demonstrates that the currently proposed IHC
criteria may be somewhat oversimplified. Until other
reliable and specific immunohistochemical markers of
malignant transformation in HCA are identified, mo-
lecular testing of LFAPB-positive HCA may be the best
strategy to identify some of the lesions requiring further
clinical management. In this context, next-generation
sequencing offers a straightforward, highly sensitive,
and accurate option for biopsies with equivocal immu-
nohistochemical results.
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